KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Short-term Investments: 2017-2024

Historic Short-term Investments for Moderna (MRNA) over the last 8 years, with Dec 2024 value amounting to $5.1 billion.

  • Moderna's Short-term Investments fell 35.44% to $3.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 billion, marking a year-over-year decrease of 35.44%. This contributed to the annual value of $5.1 billion for FY2024, which is 10.51% down from last year.
  • Moderna's Short-term Investments amounted to $5.1 billion in FY2024, which was down 10.51% from $5.7 billion recorded in FY2023.
  • Over the past 5 years, Moderna's Short-term Investments peaked at $6.7 billion during FY2022, and registered a low of $2.0 billion during FY2020.
  • For the 3-year period, Moderna's Short-term Investments averaged around $5.8 billion, with its median value being $5.7 billion (2023).
  • In the last 5 years, Moderna's Short-term Investments spiked by 128.80% in 2020 and then declined by 14.93% in 2023.
  • Yearly analysis of 5 years shows Moderna's Short-term Investments stood at $2.0 billion in 2020, then soared by 95.51% to $3.9 billion in 2021, then soared by 72.65% to $6.7 billion in 2022, then declined by 14.93% to $5.7 billion in 2023, then fell by 10.51% to $5.1 billion in 2024.